Press Releases
Merck
-
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments) PR Newswire NEW YORK , May 14, 2012 /PRNewswire/ -- Reportlinker.com...
-
F-star Appoints New CEO, COO, and VP of Development and Expands Operations in Cambridge, UK
Business Progresses Internal Pipeline, Further Advancing the mAb2 Bispecific Antibody Platform F-star , a leader in the development of novel bispecific antibodies, is pleased to announce the appointment of Dr. John Haurum as Chief...
-
Heska Reports $0.11 in Net Income Per Share for First Quarter of 2012
Heska Reports $0.11 in Net Income Per Share for First Quarter of 2012 Gross Margin Increases 400 Basis Points to 46.5% Year over Year PR Newswire LOVELAND, Colo. , May 10, 2012 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska"...
-
NMSDC To Celebrate Corporate-Minority Business Partnerships As Part Of 40th Anniversary Commemoration
NMSDC To Celebrate Corporate-Minority Business Partnerships As Part Of 40th Anniversary Commemoration PR Newswire NEW YORK , May 10, 2012 /PRNewswire-USNewswire/ -- For many years, the National Minority Supplier Development...
-
Dr. Scholl's® Survey Reveals America Is On The Move When Foot Pain Doesn't Get In The Way
Dr. Scholl's® Survey Reveals America Is On The Move When Foot Pain Doesn't Get In The Way Celebrities Megan Hilty, Wilmer Valderrama, Val Chmerkovskiy, La La Anthony, and Ivan Nova Join Dr. Scholl's® in New York City to Send a Message that...
-
Kieran Walsh Joins Rosetta as Partner in High-Growth Healthcare Vertical
Kieran Walsh Joins Rosetta as Partner in High-Growth Healthcare Vertical PR Newswire PRINCETON, N.J. , May 10, 2012 /PRNewswire/ -- Rosetta, which operates as an independent brand in the Publicis Groupe of global agencies and is one...
-
McCann Enterprise Announces Strategic Partnership with SG Blocks, Innovative Green Engineering Design/Build Firm
McCann Enterprise Announces Strategic Partnership with SG Blocks, Innovative Green Engineering Design/Build Firm PR Newswire LONDON , May 10, 2012 /PRNewswire/ -- McCann Enterprise, part of McCann Worldwide (IPG: NYSE) and SG Blocks,...
-
McCann Enterprise Announces Strategic Partnership with SG Blocks, Innovative Green Engineering Design/Build Firm
McCann Enterprise Announces Strategic Partnership with SG Blocks, Innovative Green Engineering Design/Build Firm PR Newswire LONDON , May 10, 2012 /PRNewswire/ -- McCann Enterprise, part of McCann Worldwide (IPG: NYSE) and SG Blocks,...
-
EnWave Receives Favorable PCT Review for Key Intellectual Property
EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or "the Company") announced today that the Company has received a favorable review from the Patent Cooperation Treaty ("PCT") Examiner for its Radiant Energy Vacuum ("REV") patent...
-
Prestigious Frost & Sullivan Growth Excellence Awards Conferred on Top Industry Achievers
Prestigious Frost & Sullivan Growth Excellence Awards Conferred on Top Industry Achievers PR Newswire - Twenty-seven Trailblazing Companies from Europe and Africa Honoured for their Gold-standard Performance LONDON , May 10, 2012...
-
Prestigious Frost & Sullivan Growth Excellence Awards Conferred on Top Industry Achievers
Prestigious Frost & Sullivan Growth Excellence Awards Conferred on Top Industry Achievers Twenty-seven Trailblazing Companies from Europe and Africa Honoured for their Gold-standard Performance PR Newswire LONDON , May 10, 2012...
-
Medicure Announces Commencement of Enrollment in SAVI-PCI Trial of AGGRASTAT
Medicure Inc. ( "Medicure" or the "Company") (TSX VENTURE:MPH)(PINKSHEETS:MCUJ) is pleased to announce the commencement of enrollment in SAVI-PCI ("Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention") a prospective,...
-
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others PR Newswire NEW YORK , May 10, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available...
-
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments PR Newswire NEW YORK , May 10, 2012 /PRNewswire/...
-
NicOx reports first quarter 2012 financial results
SOPHIA ANTIPOLIS, FRANCE -- (Marketwire) -- 05/10/12 -- PRESS RELEASE www.nicox.com NicOx S.A. (NYSE Euronext Paris: COX) today reports financial results for the first three months of 2012 and provides an overview of its activities. ...
Follow us
What people say
Our Partners
© 2005-2012